ArticleFrontiers in pharmacology2026
Development of a stacking model for personalized treatment of Crohn's disease: leveraging routine clinical features to forecast infliximab response.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Infliximab (IFX) is widely used for treating Crohn's disease (CD), but a significant proportion of patients experience primary non-response or loss of response. Early prediction of IFX efficacy is crucial to avoid ineffective treatment, adverse effects, and financial burden. The aim of this study was to develop a stacking model using routine clinical data to predict IFX clinical response. Method: This retrospective cohort study enrolled CD patients initiating IFX therapy between January 2019 and December 2025. Feature selection was performed using statistical analysis and Least Absolute Shrinkage and Selection Operator (LASSO) regression. Base models (Elastic Net, Support Vector Machine, Random Forest, XGBoost) were built and integrated into a stacking model. Model performance was evaluated using the Area Under the Receiver Operating Characteristic Curve (AUROC), accuracy, precision, sensitivity, specificity, recall, and F-score on a hold-out testing set. Class imbalance was addressed using the Synthetic Minority Over-sampling Technique. Result: A total of 319 patients were enrolled, comprising 237 responders and 82 non-responders, reflecting a class imbalance. An independent dataset containing 43 patients was used for temporal validation. LASSO regression identified five key predictors: erythrocyte sedimentation rate, C-reactive protein, Crohn's disease activity index, red blood cell count, and diagnostic age. The stacking model, composed of Elastic Net and Random Forest, achieved an AUROC of 0.897 (95% CI: 0.832-0.956) on the validation set and 0.874 (95% CI: 0.749-0.957) on the testing set, demonstrating robust predictive performance. Conclusion: The developed stacking model effectively predicts IFX response using readily available clinical variables, representing a preliminary step toward personalized treatment planning. Prospective validation is required before clinical implementation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.